Phil Skolnick - 27 Jun 2022 Form 4 Insider Report for OPIANT PHARMACEUTICALS, INC.

Role
Chief Scientific Officer
Signature
/s/ Phil Skolnick
Issuer symbol
N/A
Transactions as of
27 Jun 2022
Net transactions value
$0
Form type
4
Filing time
29 Jun 2022, 16:03:46 UTC
Previous filing
27 Jan 2022
Next filing
15 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OPNT Common Stock Award $0 +2,000 +8.9% $0.000000 24,445 27 Jun 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the acquisition of shares upon the determination on June 27, 2020 by the Compensation and Human Capital Committee of the Board of Directors of the Issuer that the performance conditions were met with respect to a portion of the performance stock units granted to the Reporting Person on January 4, 2022.